T-Cell Engagers Show Promise for Autoimmune Diseases
Bispecific T-cell engagers (TCEs) are demonstrating promise in the compassionate use treatment of refractory autoimmune connective tissue diseases, according to a recent report. This area of immunotherapy represents a potential new frontier for patients with conditions that have not responded to existing treatments.
- This therapeutic approach is adapted from oncology, where T-cell engagers have been successfully used to treat various cancers, including lung cancer, melanoma, and blood cancers. - The technology works by using a lab-engineered bispecific antibody that acts as a bridge: one end of the antibody latches onto a T-cell (a type of immune cell), and the other end grabs onto a target cell, bringing them together to destroy the target. - In the context of autoimmune diseases, instead of targeting cancer cells, the therapy is being redirected to eliminate the patient's own B-cells, which are responsible for creating the harmful autoantibodies that attack healthy tissues. - Current treatments for severe autoimmune diseases often rely on broadly suppressing the entire immune system with drugs like corticosteroids, which can lead to a higher risk of infection and other long-term side effects. - In one recent study, 10 patients with a variety of refractory autoimmune diseases, including Sjögren's syndrome and systemic sclerosis, were treated with a T-cell engager called teclistamab; all but one showed significant improvement, and six entered drug-free remission. - The development of such therapies involves a wide range of life science careers, from computational biologists who model the antibody structures and bioinformaticians who analyze patient data, to clinical research coordinators and physicians who design and run the patient trials.
